The logic behind the approach is elegantly chemical. Bone is a composite material: a proteinaceous organic scaffold, dominated by collagen, is reinforced by crystals of a calcium-phosphate mineral closely related to hydroxyapatite. Osteoporosis, the thinning disease that affects millions of older adults, primarily involves loss of bone mass and deterioration of microarchitecture, while the mineralization of the tissue that remains stays largely normal. Osteomalacia, by contrast, is a disorder of mineralization itself, often tied to vitamin D deficiency and chronic kidney disease, in which abundant soft matrix fails to harden properly. A measurement that captures only total density, as conventional X-ray absorptiometry does, cannot reliably separate these conditions. But a measurement that reports matrix density and mineral density independently, and their ratio, in principle can.

That is precisely what the new technique delivers. The researchers used a custom-built radiofrequency coil tuned simultaneously to two nuclear species: protons, the workhorse of MRI, and phosphorus-31, the nucleus at the heart of bone mineral. In the proton channel, they applied a water- and fat-suppressed solid-state acquisition, often described in the literature as WASPI, which selectively detects the short-signal-lifetime protons bound within the organic matrix of bone while discarding the overwhelming signals from free water and marrow fat. In the phosphorus channel, they exploited the fact that phosphorus in rigid bone mineral has an extremely short signal lifetime that ordinary clinical MRI cannot capture, but that solid-state projection methods can. The result is two quantitative three-dimensional maps of the same specimen: one of organic matrix density, one of mineral density.

Dividing one by the other yields a quantity the team calls the Extent of Bone Mineralization, or EBM, essentially a mineral-to-matrix ratio that serves as a direct, imaging-based readout of how well the bone tissue is mineralized. This is the kind of information that, until now, generally required invasive bone biopsy and histomorphometry to obtain, particularly in the context of renal osteodystrophy, the bone disorder that accompanies chronic kidney disease and whose diagnosis still frequently depends on biopsy. An imaging surrogate for mineralization status, delivered without ionizing radiation, would be a meaningful addition to the clinical toolkit if it can be translated.

To test the concept, the investigators studied fifteen rats divided into three groups: healthy controls, ovariectomized animals modeling postmenopausal osteoporosis, and animals rendered vitamin D deficient and subjected to a five-sixths nephrectomy, a standard model of renal osteodystrophy with impaired mineralization. Excised femurs were imaged ex vivo on a 7-Tesla research scanner using the double-tuned coil. The imaging-derived matrix and mineral densities were then validated against two independent reference standards: micro-computed tomography, which provides high-resolution structural and density information, and gravimetric chemical analysis of the same bones.

The validation results were strong. MRI-derived measures of both matrix and mineral density correlated with the reference measurements with correlation coefficients between 0.85 and 0.89, with p-values below 0.001, indicating that the magnetic resonance numbers track the true compositional quantities closely. In the cortical shell of the bone, the MRI-based matrix volume and mineral density declined progressively across the three groups, from controls to osteoporotic to renal-osteodystrophy animals, exactly as the underlying biology would predict. Trabecular measurements, the spongy interior network of bone struts, showed more scatter, which the authors attribute to the greater microarchitectural heterogeneity of that compartment at the resolution achievable in these experiments.

The most diagnostic finding concerned the mineralization ratio itself. In the ovariectomized rats, whose disease mimics osteoporosis, EBM remained close to normal, reflecting the fact that osteoporosis removes bone but leaves the remaining tissue appropriately mineralized. In the vitamin D deficient nephrectomized rats, EBM was markedly altered, consistent with the defective mineralization that defines osteomalacia and renal osteodystrophy. In other words, the ratio did what it was designed to do: it separated a disease of bone quantity from a disease of bone quality. Multivariate analysis of variance confirmed statistically significant effects of both disease group and bone region, with p-values below 0.001.

The team then pushed the analysis a step further, asking whether the combined imaging features could actually classify individual specimens into the correct diagnostic category. Using multinomial logistic regression on cortical and trabecular predictors drawn from the two nuclei, they achieved 86.7 percent cross-validated accuracy in assigning bones to the control, osteoporotic, or renal-osteodystrophy groups. For a proof-of-concept study in a small animal cohort, that level of separability is encouraging, and it suggests that compositional imaging could eventually help clinicians distinguish patients who need antiresorptive therapy from those whose disordered mineralization calls for a very different treatment strategy, such as correction of vitamin D and phosphate metabolism in kidney disease.

The authors are careful, and rightly so, about the limits of the current work. Each specimen required several hours of acquisition time on a high-field research scanner, which places the technique firmly in the realm of analytical feasibility rather than clinical readiness. All measurements were performed ex vivo on excised femurs, and the animal cohort was small. The researchers note that substantial acceleration of the acquisition and validation in living subjects and larger cohorts will be required before the method approaches the clinic, and they recommend treating the Extent of Bone Mineralization as a promising candidate compositional marker rather than an established diagnostic quantity.

Even with those caveats, the study represents a notable step for quantitative bone imaging. It builds on decades of groundwork in solid-state MRI of calcified tissues, including earlier demonstrations of phosphorus-31 imaging of hydroxyapatite, water- and fat-suppressed proton imaging of bone matrix, and prior combined proton-phosphorus feasibility work in human cortical bone. What this study adds is a unified, validated framework in which matrix density, mineral density and their ratio are measured together in disease models, and shown to carry genuine diagnostic information. If faster acquisition sequences, improved coils and in vivo protocols can close the speed gap, radiation-free MRI that reports not just how much bone a patient has but what that bone is made of could reshape how osteoporosis, renal osteodystrophy and other metabolic bone diseases are diagnosed and monitored.

Subject of Research: Multinuclear solid-state MRI for quantitative assessment of bone matrix and mineral densities in rat models of osteoporosis and renal osteodystrophy

Article Title: A Combined 1H and 31P Magnetic Resonance Imaging Technique to Assess Bone Matrix and Mineral Densities in Rats with Osteoporosis and Osteomalacia

Article References: Kassey, V. B., Walle, M., Yeritsyan, D., Egan, J., Kassey, A. R., Hedayatzadeh, A., Wu, Y., Snyder, B. D., Rodriguez, E. K., Ackerman, J. L., & Nazarian, A. (2026). A Combined 1H and 31P Magnetic Resonance Imaging Technique to Assess Bone Matrix and Mineral Densities in Rats with Osteoporosis and Osteomalacia. Annals of Biomedical Engineering. https://doi.org/10.1007/s10439-026-04391-4

Image Credits: AI Generated

DOI: 10.1007/s10439-026-04391-4

Keywords: solid-state MRI, multinuclear MRI, bone mineral density, bone matrix, osteoporosis, osteomalacia, renal osteodystrophy, bone mineralization, phosphorus-31 MRI, quantitative imaging, rat models, Extent of Bone Mineralization

Peritoneal dialysis is a form of renal replacement therapy in which the lining of the patient’s abdomen filters waste products from the blood, offering an alternative to hemodialysis for many people with end-stage kidney disease. Although fractures are a recognized and serious complication of chronic kidney disease in general, contributing to pain, disability, institutionalization, and death, patients treated with peritoneal dialysis have been comparatively understudied. Most fracture research in dialysis populations has centered on hemodialysis, leaving clinicians with limited evidence to guide fracture prevention decisions for the peritoneal dialysis cohort. The new study was designed to fill that gap by quantifying how often fragility fractures occur during peritoneal dialysis follow-up, identifying the factors that predict them, and testing whether a standard risk calculator works in this setting.

The research team conducted a single-center retrospective cohort study at their Portuguese institution, including adult patients who had been receiving peritoneal dialysis for at least twelve months. In total, 325 patients were analyzed, with a mean age of 53 years and a majority, 57 percent, being male. Fragility fractures occurring during peritoneal dialysis follow-up were identified through two complementary routes: systematic review of clinical records and review of spine radiographs. This dual approach mattered, because it allowed the investigators to capture vertebral fractures that had never caused symptoms and therefore never prompted clinical attention. Vascular calcification, a hallmark of the disordered mineral metabolism that accompanies kidney failure, was quantified using the Adragão vascular calcification score, a simple radiographic tool originally developed for hemodialysis patients that evaluates calcification in the pelvic and hand arteries on plain films.

To evaluate whether existing risk tools could be applied to these patients, the researchers calculated FRAX® probabilities for each individual without incorporating bone mineral density measurements. FRAX®, the Fracture Risk Assessment Tool developed by the World Health Organization collaboration led by John Kanis and colleagues, integrates clinical risk factors such as age, sex, prior fracture, parental hip fracture history, smoking, glucocorticoid use, and secondary causes of osteoporosis to estimate ten-year fracture probability. The investigators then used logistic regression to determine which variables independently predicted fracture occurrence, and constructed receiver operating characteristic curves to judge how well FRAX® discriminated between patients who fractured and those who did not. Statistical analyses were performed by the joint first authors, Diz-Lopes and Fernandes, who contributed equally to the work.

The headline finding was that fragility fractures were far from rare. Thirty-two of the 325 patients, or 9.8 percent, sustained at least one fragility fracture during peritoneal dialysis follow-up. Strikingly, the majority of these were asymptomatic vertebral fractures, accounting for 23 of the 32 fracture events, or 7.1 percent of the entire cohort. In other words, roughly seven in every hundred peritoneal dialysis patients in the study had vertebral fractures that were detectable on radiographs but had produced no clinical symptoms. Only a minority of fractures were the clinically obvious events, such as hip or other peripheral fractures, that typically bring a dialysis patient to medical attention.

When the researchers ran multivariable logistic regression to isolate independent predictors of fracture, two factors emerged. A history of previous fracture was the strongest, conferring nearly a five-fold increase in odds of sustaining a new fragility fracture during follow-up, with an odds ratio of 4.85 and a 95 percent confidence interval of 1.22 to 19.27. This aligns with a large body of literature, including a 2023 meta-analysis used to update FRAX® itself, establishing prior fracture as one of the most potent predictors of subsequent fracture in the general population. The second independent predictor was a higher Adragão vascular calcification score, with an odds ratio of 2.10 and a 95 percent confidence interval of 1.10 to 4.03, meaning each increment in the score roughly doubled the odds of fracture.

The link between vascular calcification and skeletal fragility is a recurring theme in dialysis research. Prior studies in hemodialysis populations, including work by Fusaro and colleagues using quantitative morphometry and by Rodriguez-Garcia and colleagues in the Asturias cohort, have documented strong associations between vascular calcifications, vertebral fractures, and mortality. The prevailing explanation, articulated by Cannata-Andia and colleagues, is that the connections between vascular and bone health run deep: the same disturbances of mineral metabolism, inflammation, and bone turnover that drive calcium deposition in arteries can also impair bone quality. Some investigators, including Adragao’s group, have shown that higher mineralized bone volume is associated with lower plain radiographic vascular calcification scores, suggesting that the two processes may be two faces of a shared underlying pathology. The new peritoneal dialysis data extend this vascular-bone axis to a population where it had not been well characterized.

The performance of FRAX® in this cohort was the study’s most sobering result. The tool showed only modest discriminatory ability for any fragility fracture, with an area under the receiver operating characteristic curve of 0.69. An AUC of 0.69 falls well short of what is generally considered good discrimination and implies limited practical utility for individual decision-making. More concerning still, sensitivity at the standard intervention thresholds was very low, meaning that the great majority of patients who actually fractured would not have been flagged for treatment under existing guidelines. Notably, this remained true even when the researchers classified chronic kidney disease as a secondary cause of osteoporosis within the FRAX® algorithm, the most favorable adjustment available to them. The conclusion is that FRAX® systematically underestimates fracture risk in peritoneal dialysis patients.

This finding has context in a growing literature on FRAX® and kidney disease. Studies by Whitlock and colleagues in 2019 showed that FRAX® can predict fracture risk in chronic kidney disease populations, while other work by Przedlacki and colleagues in hemodialysis and by Hayashi and colleagues in Japanese hemodialysis patients has produced more mixed results. A recent overview of systematic reviews by Cruz-Priego and colleagues in 2025 examined the predictive capacity of fracture risk assessment tools broadly and highlighted persistent questions about their transportability across populations. The FRAX® algorithm was derived from population-based cohorts that excluded or underrepresented patients with advanced kidney disease, whose bone disease differs fundamentally from postmenopausal or age-related osteoporosis. In dialysis patients, the spectrum of skeletal pathology, encompassing high-turnover bone disease, adynamic bone disease, and mixed uremic osteodystrophy under the umbrella of chronic kidney disease-mineral and bone disorder, is far more heterogeneous than the bone loss captured by standard osteoporosis models.

The implications for clinical practice are significant. The European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4 to G5D, published by Evenepoel and colleagues in 2021, acknowledged the difficulty of distinguishing the causes of bone fragility in advanced kidney disease, and recent KDIGO Controversies Conference conclusions from Ketteler and colleagues in 2025 similarly emphasized unresolved questions in chronic kidney disease-mineral and bone disorder. Given that bone mineral density by dual-energy X-ray absorptiometry, the cornerstone of conventional osteoporosis assessment, may not fully capture bone quality in uremic patients, and given that DXA studies in peritoneal dialysis patients have shown discordance between lumbar spine and femoral neck measurements, the study’s authors argue that improved fracture risk assessment strategies tailored specifically to peritoneal dialysis patients are needed. The identification of vascular calcification as an independent risk factor is particularly appealing from a practical standpoint, because the Adragão score relies on simple plain radiographs already obtained for other reasons in many dialysis patients, making it a feasible and inexpensive addition to risk stratification.

The authors are careful to frame their findings within the limits of the study design. As a retrospective, single-center cohort of 325 patients at one Portuguese institution, the study cannot establish causation, is subject to the ascertainment biases inherent in clinical record review, and may not generalize to peritoneal dialysis populations with different demographic or clinical characteristics, or to healthcare systems with different screening practices. The confidence interval around the odds ratio for prior fracture is wide, from 1.22 to 19.27, reflecting the relatively small number of fracture events and the uncertainty that accompanies estimates derived from them. Verbal informed consent was obtained from subjects given the retrospective design, and ethical approval was granted by the local ethics committee of Hospital de São João under approval number CE 90/2024. The authors declared no conflicts of interest and no external funding. Data supporting the findings are available from the corresponding author upon reasonable request.

Even with these caveats, the study delivers a clear message to nephrologists and rheumatologists who care for peritoneal dialysis patients. Fragility fractures are common in this group, driven disproportionately by vertebral fractures that remain invisible unless deliberately sought, and the standard risk calculator that guides osteoporosis treatment decisions in the general population cannot be trusted here. Patients with a prior fracture or with vascular calcification on plain radiographs deserve heightened vigilance. Until tools validated specifically for the peritoneal dialysis population are developed, clinicians may need to rely on clinical judgment, attention to prior fracture history, and simple radiographic markers of vascular calcification to identify those at greatest skeletal risk. As the population of people living long-term on dialysis grows, and as reports of increasing hip fractures in both hemodialysis and peritoneal dialysis patients accumulate, closing the evidence gap in bone health for peritoneal dialysis patients becomes an increasingly urgent priority for the kidney and bone research communities alike.